Subscribe to magazine
Subscribe to newsletters
Computed Tomography (CT)
Magnetic Resonance Imaging (MRI)
Radiation Dose management
Intravascular imaging systems
Peripheral Artery Disease
Leads, implantable devices
Implantable cardioverter defibrillators (ICD)
Cardiac resynchronization therapy devices (CRT)
Heart Valve Technology
Left atrial appendage (LAA) occluders
Structural heart occluders/closure devices
Clinical decision support
202, 279 Midpark Way SE
Calgary, AB, CANADA, T2X 1M2
November 15, 2013
Drug Lowers Inflammation, MACE Events While Regressing Atheroma in High Risk CVD Patients
Resverlogix Corp. announced two additional results from the ongoing analysis of its Phase 2b ASSURE ...
September 28, 2011
Resverglogix Study Examines Atherosclerotic Plaque Regression Drug
September 28, 2011 — A clinical trial by Resverlogix Corp. is evaluating the early effects of a new drug compound in...
December 23, 2009
Cleveland Clinic Tests Drug to Increase HDL Production
December 23, 2009 – The Cleveland Clinic this week initiated a phase II trial examining a new oral therapy for the...
October 02, 2009
Resverlogix RVX-208 Clinical Trial Demonstrates Key Reverse Cholesterol Transport Markers
October 2, 2009 – Resverlogix Corp. said this week results from the company's second clinical trial for the drug RVX-...
Scranton Gillette Communications
. All Rights Reserved.